Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 161 to 170 of 1090 total matches.
Ixabepilone (Ixempra) for Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jan 28, 2008 (Issue 1278)
. CYP3A and drug interactions. Med Lett Drugs Ther 2005;
47:54.
6. Price according to AWP listings ...
Ixabepilone (ix ab ep' i lone; Ixempra - Bristol-Myers Squibb), a semisynthetic epothilone analog, has been approved by the FDA for treatment of advanced breast cancer. It is indicated for use in combination with capecitabine (Xeloda - Roche) for treatment of locally advanced or metastatic breast cancer after failure of an anthracycline such as doxorubicin (Adriamycin) and a taxane such as paclitaxel (Taxol, and others). It is also approved as monotherapy for treatment of metastatic or locally advanced breast cancer after an anthracycline, a taxane and capecitabine have...
PARP Inhibitors for Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017 (Issue 1535)
with placebo
(19.1 vs 5.5 months).7
Drug Interactions – Olaparib is metabolized primarily
by CYP3A4/5 ...
Three oral poly(ADP-ribose) polymerase (PARP)
inhibitors have been approved by the FDA for treatment
of advanced, recurrent ovarian cancer. Olaparib
(Lynparza – AstraZeneca), niraparib (Zejula – Tesaro),
and rucaparib (Rubraca – Clovis) are each approved
for somewhat different indications and for patients
with different biomarkers (see Table 2).
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017 (Issue 1531)
concentrations.6 Some potentially
significant drug interactions with Mavyret are listed in
Table 3.
VOSEVI ...
The FDA has approved Mavyret (Abbvie) and Vosevi
(Gilead), two new fixed-dose combinations of direct-acting
antiviral (DAA) drugs, for treatment of chronic
hepatitis C virus (HCV) infection caused by any of the
six major HCV genotypes in patients without cirrhosis
or with compensated cirrhosis. Both are approved for
use in treatment-experienced patients. Mavyret is also
approved for treatment-naive patients.
Bromfenac for Analgesia
The Medical Letter on Drugs and Therapeutics • Oct 10, 1997 (Issue 1011)
serious than it appeared to
be in clinical trials.
DRUG INTERACTIONS — Phenytoin (Dilantin, and others ...
Bromfenac sodium (Duract - Wyeth-Ayerst), a nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration (FDA) and is being heavily advertised as an alternative to narcotics for short-term treatment of pain.
Phenylpropanolamine and Other OTC Alpha-Adrenergic Agonists
The Medical Letter on Drugs and Therapeutics • Dec 11, 2000 (Issue 1094)
effects. All alpha-adrenergic agonists interact with many other drugs; interactions with a monoamine ...
The US Food and Drug Administration has ordered removal of phenylpropanolamine from over-the-counter cold remedies and weight loss aids. The FDA based its decision on a recent study showing an increased risk of hemorrhagic stroke in young women taking the drug.
Rocuronium - A New Neuromuscular Blocker
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994 (Issue 928)
in Red Book 1994
or the manufacturer
3. Divided doses
DRUG INTERACTIONS — Like other neuromuscular ...
Rocuronium bromide (Zemuron - Organon), a new short-onset, intermediate-acting, nondepolarizing neuromuscular blocking drug, is now available in the USA for intravenous use. It is being promoted particularly for use in rapid endotracheal intubation.
Rilonacept (Arcalyst) for Recurrent Pericarditis
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
DRUG INTERACTIONS — Use of an IL-1 inhibitor with
a TNF inhibitor has been associated ...
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 (IL-1)
antagonist that has been available for years for
treatment of cryopyrin-associated periodic syndromes,
has now been approved by the FDA for treatment
of recurrent pericarditis and prevention of further
recurrences in patients ≥12 years old. It is the first drug
to be approved in the US for this indication. Anakinra
(Kineret), an IL-1 receptor antagonist FDA-approved for
treatment of rheumatoid arthritis, has been used off-label
for years for treatment of recurrent pericarditis.
In Brief: A New Indication for Dabrafenib (Tafinlar) and Trametinib (Mekinist) Combination Therapy (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
, dry skin, dermatitis
acneiform, abdominal pain, and paronychia also
occurred.
DRUG INTERACTIONS ...
The oral kinase inhibitors dabrafenib (Tafinlar – GSK)
and trametinib (Mekinist – Novartis) have received
accelerated approval by the FDA for use together
for a fifth indication: treatment of unresectable or
metastatic solid tumors with a BRAF V600E mutation
in patients ≥6 years old who have progressed
following prior treatment and have no satisfactory
alternative treatment options. The combination is not
approved for treatment of colorectal cancer because
of known intrinsic resistance to BRAF inhibition and
dabrafenib is not approved for use in patients with
wild-type BRAF...
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e26-7 doi:10.58347/tml.2023.1669f | Show Introduction Hide Introduction
Correction: Resperate for Hypertension
The Medical Letter on Drugs and Therapeutics • Aug 27, 2007 (Issue 1268)
, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D ...
(Med Lett Drugs Ther 2007; 49:55) The second sentence in the article ("The FDA does not require proof of effectiveness for approval of devices with minimal potential for harm, such as this one.") should have been omitted. It would apply to a Class I device, but the FDA has classified Resperate as a Class II device.
Correction: Low Dose Transdermal Estrogens
The Medical Letter on Drugs and Therapeutics • Oct 08, 2007 (Issue 1271)
, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D ...
The Medical Letter article (Med Lett Drugs Ther 2007; 49:71) on Low-Dose Transdermal Estrogens said that Elestrin has been marketed in Europe since 1976. Actually it is EstroGel (Ascend Therapeutics), a similar product, that has been available in Europe since 1976.